EVOLTRA Side Effects

7020921-3 | Delirium, Diarrhoea, Febrile Neutropenia, Infection, Metabolic Acidosis, Pancytopenia, Respiratory Failure
on Sep 21, 2010 Male patient from NETHERLANDS , weighting 185.2 lb, was diagnosed with acute leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: delirium, diarrhoea, febrile neutropenia, infection (What is infection?), metabolic acidosis, pancytopenia, respiratory failure. Evoltra dosage: 31 Mg, Qod. During the same period patient was treated with CYTARABINE (200 Mg, Qd) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (21 Mg, Qod) (View Idarubicin Hcl Review and Idarubicin Hcl Label ).

7020404-0 | Delirium, Dyspnoea, Enterococcal Infection, Haematocrit Decreased, Haematuria, Haemoglobin Decreased, Platelet Count Decreased, Pyrexia
Patient was taking Evoltra (View Usage). Patient had the following side effects: delirium, dyspnoea, enterococcal infection, haematocrit decreased, haematuria, haemoglobin decreased, platelet count decreased, pyrexia on Sep 23, 2010 from NETHERLANDS Additional patient health information: Female patient , weighting 163.1 lb, was diagnosed with prophylaxis, pyrexia, delirium and. Evoltra dosage: 10.5 Mg, Unk. During the same period patient was treated with CYTARABINE (370 Mg, Unk) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (22 Mg, Unk) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), IMIPENEM AND CILASTATIN (2000 Mg, Unk) (View Imipenem And Cilastatin Review and Imipenem And Cilastatin Label ), TOBRAMYCIN (360 Mg, Unk) (View Tobramycin Review and Tobramycin Label ), ESOMEPRAZOLE (20 Mg, Unk) (View Esomeprazole Review and Esomeprazole Label ), TRANEXAMIC ACID (4000 Mg, Unk) (View Tranexamic Acid Review and Tranexamic Acid Label ), VANCOMYCIN (2000 Mg, Unk) (View Vancomycin Review and Vancomycin Label ), HALOPERIDOL (9 Mg, Unk) (View Haloperidol Review and Haloperidol Label ).

7017624-8 | Dermatitis Exfoliative
Adverse event was reported on Sep 16, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 10 Mg/m2, Unk) was diagnosed with acute myeloid leukaemia and. Location: NETHERLANDS , weighting 163.1 lb, After Evoltra was administered, patient had the following side effects: dermatitis exfoliative. During the same period patient was treated with AMSACRINE (120 Mg/m2, Unk) (View Amsacrine Review and Amsacrine Label ), CYTARABINE (1000 Mg/m2, Unk) (View Cytarabine Review and Cytarabine Label ), TRAMADOL (200 Mg, Qd) (View Tramadol Review and Tramadol Label ), MORPHINE (40 Mg, Qd) (View Morphine Review and Morphine Label ).

7013355-9 | Serotonin Syndrome
on Sep 15, 2010 Female patient from NETHERLANDS , weighting 121.3 lb, was diagnosed with acute lymphocytic leukaemia, acute leukaemia, prophylaxis and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: serotonin syndrome. Evoltra dosage: 32 Mg, Qdx5. During the same period patient was treated with PEG ASPARAGINASE (600 Iu, Unk) (View Peg-asparaginase Review and Peg-asparaginase Label ), DAUNORUBICIN HCL (65 Mg, Unk) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), PREDNISOLONE (65 Mg, Unk) (View Prednisolone Review and Prednisolone Label ), DEXAMETHASONE (4 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (15 Mg, Unk) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (2 Mg, Unk) (View Vincristine Review and Vincristine Label ), ESOMEPRAZOLE MAGNESIUM (40 Mg, Unk) (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), ACETAMINOPHEN (500 Mg, Unk) (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.


7009128-3 | Febrile Neutropenia, Haemorrhage, Infection
on Sep 13, 2010 Female patient from UNITED KINGDOM , weighting 113.1 lb, was diagnosed with acute myeloid leukaemia, prophylaxis, febrile neutropenia, antiviral treatment, antifungal prophylaxis and was treated with Evoltra (View Usage). Patient had the following side effects: febrile neutropenia, haemorrhage, infection (What is infection?). Evoltra dosage: 60 Mg, Qdx5. During the same period patient was treated with DAUNOXOME (92 Mg, Qod) (View Daunoxome Review and Daunoxome Label ), CIPROFLOXACIN (250 Mg, Unk) (View Ciprofloxacin Review and Ciprofloxacin Label ), NORETHISTERONE (10 Mg, Tid) (View Norethisterone Review and Norethisterone Label ), VALACYCLOVIR (500 Mg, Bid) (View Valacyclovir Review and Valacyclovir Label ), COTRIM (480 Mg, Bid) (View Cotrim Review and Cotrim Label ), OMEPRAZOLE (20 Mg, Qd) (View Omeprazole Review and Omeprazole Label ), TRANEXAMIC ACID (1 G, Tid) (View Tranexamic Acid Review and Tranexamic Acid Label ). Patient was hospitalized.

7001090-2 | Bone Marrow Failure, Human Herpesvirus 6 Infection
Patient was taking Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: bone marrow failure, human herpesvirus 6 infection on Sep 10, 2010 from ITALY Additional patient health information: Female patient , weighting 145.5 lb, was diagnosed with acute myeloid leukaemia, prophylaxis and. Evoltra dosage: 22.5 Mg/m2, Qdx5, Consolidation. During the same period patient was treated with CYTARABINE (1 G/m2, Qdx5, Consolidation) (View Cytarabine Review and Cytarabine Label ), MYLOTARG (6 Mg/m2, Once, Induction) (View Mylotarg Review and Mylotarg Label ), VFEND (200 Mg, Bid) (View Vfend Review and Vfend Label ), CIPRALEX (10 Mg, Qd) (View Cipralex Review and Cipralex Label ), LEVOFLOXACIN (800 Mg, Qd) (View Levofloxacin Review and Levofloxacin Label ).

7000884-7 | Bone Marrow Failure, Septic Shock
Adverse event was reported on Sep 10, 2010 by a Female patient taking Evoltra (View Usage) (Dosage: 22.5 Mg/m2, Qdx5) was diagnosed with acute myeloid leukaemia, prophylaxis and. Location: ITALY , weighting 132.3 lb, Patient experienced the following unwanted or unexpected effects: bone marrow failure, septic shock. During the same period patient was treated with CYTARABINE (1 G/m2, Qdx5) (View Cytarabine Review and Cytarabine Label ), MYLOTARG (6 Mg/m2, Once) (View Mylotarg Review and Mylotarg Label ), LEVOFLOXACIN (500 Mg, Qd) (View Levofloxacin Review and Levofloxacin Label ), ITRACONAZOLE (400 Mg, Qd) (View Itraconazole Review and Itraconazole Label ), ALLOPURINOL (30 Mg, Qd) (View Allopurinol Review and Allopurinol Label ), AMITRIPTYLINE HCL (4 Gtt, Qd) (View Amitriptyline Hcl Review and Amitriptyline Hcl Label ), HALCION (0.125 Mg, Qd) (View Halcion Review and Halcion Label ).

7000856-2 | Bone Marrow Failure, Multi-organ Failure
on Sep 10, 2010 Female patient from ITALY , weighting 123.5 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient had the following side effects: bone marrow failure, multi-organ failure. Evoltra dosage: 22.5 Mg/m2, Qdx5. During the same period patient was treated with CYTARABINE (1 G/m2, Qdx5) (View Cytarabine Review and Cytarabine Label ), MYLOTARG (6 Mg/m2, Once Day 6) (View Mylotarg Review and Mylotarg Label ).

6987147-0 | Central Nervous System Lesion, Cerebral Haemorrhage, Chloroma, Colitis, Coma, Febrile Neutropenia, Fungal Infection, Hemiparesis
on Sep 09, 2010 Male patient from NETHERLANDS , weighting 162.9 lb, was diagnosed with acute myeloid leukaemia, bacteraemia, prophylaxis, pyrexia, blood potassium decreased, candidiasis and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: central nervous system lesion, cerebral haemorrhage, chloroma, colitis, coma, febrile neutropenia, fungal infection (What is fungal infection?), hemiparesis. Evoltra dosage: 112 Iv, D 2, 4, 6, 8 + 10. During the same period patient was treated with CYTARABINE (100 Mg/m2 Cont Infus D1-10) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (10 Mg/m2, D1,3 And 5) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), VANCOMYCIN (1250 Mg, Unk) (View Vancomycin Review and Vancomycin Label ), PANTAZOL (Unk) (View Pantazol Review and Pantazol Label ), ACETAMINOPHEN (500 Mg, Unk) (View Acetaminophen Review and Acetaminophen Label ), CIPROXIN (500 Mg, Bid) (View Ciproxin Review and Ciproxin Label ), KALIUMCHLORIDE (20 Mmol/l, Tid) (View Kaliumchloride Review and Kaliumchloride Label ), CASPOFUNGIN (750 Mg, Tid) (View Caspofungin Review and Caspofungin Label ). Patient was hospitalized.

6972624-9 | Acute Myeloid Leukaemia, Diarrhoea, Hypotension, Myocardial Infarction, Renal Failure Acute
Patient was taking Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: acute myeloid leukaemia, diarrhoea, hypotension, myocardial infarction, renal failure acute on Sep 07, 2010 from UNITED KINGDOM Additional patient health information: Male patient , weighting 186.7 lb, was diagnosed with acute myeloid leukaemia and. Evoltra dosage: 39 Mg, Qd. During the same period patient was treated with ACETAMINOPHEN (1 G, Unk) (View Acetaminophen Review and Acetaminophen Label ), ENOXAPARIN SODIUM (200 Mg, Unk) (View Enoxaparin Sodium Review and Enoxaparin Sodium Label ), ACYCLOVIR SODIUM (200 Mg, Unk) (View Acyclovir Sodium Review and Acyclovir Sodium Label ), ALLOPURINOL (300 Mg, Unk) (View Allopurinol Review and Allopurinol Label ), DIGOXIN (187.5 Mg, Unk) (View Digoxin Review and Digoxin Label ), ONDANSETRON (8 Mg, Unk) (View Ondansetron Review and Ondansetron Label ), SEPTRIN (960 Mg, Unk) (View Septrin Review and Septrin Label ), FLUCONAZOLE (50 Mg, Unk) (View Fluconazole Review and Fluconazole Label ). Patient was hospitalized.

6966808-3 | Serotonin Syndrome
Adverse event was reported on Aug 24, 2010 by a Female patient taking Evoltra (View Usage) (Dosage: 20 Mg/m2, Unk) was diagnosed with acute leukaemia and. Location: NETHERLANDS , weighting 121.3 lb, Patient had the following side effects: serotonin syndrome. During the same period patient was treated with PEG ASPARAGINASE (600 Iu, Unk) (View Peg-asparaginase Review and Peg-asparaginase Label ), DAUNORUBICIN HCL (65 Mg, Unk) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), PREDNISOLONE (65 Mg, Unk) (View Prednisolone Review and Prednisolone Label ), DEXAMETHASONE (4 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), METHOTREXATE (15 Mg, Unk) (View Methotrexate Review and Methotrexate Label ), VINCRISTINE (2 Mg, Unk) (View Vincristine Review and Vincristine Label ), ESOMEPRAZOLE MAGNESIUM (40 Mg, Unk) (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), ACETAMINOPHEN (500 Mg, Unk) (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

6957493-5 | Central Nervous System Lesion, Cerebral Haemorrhage, Chloroma, Colitis, Coma, Febrile Neutropenia, Fungal Infection, Hemiparesis
on Aug 23, 2010 Male patient from NETHERLANDS , weighting 162.9 lb, was diagnosed with acute leukaemia, acute myeloid leukaemia and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: central nervous system lesion, cerebral haemorrhage, chloroma, colitis, coma, febrile neutropenia, fungal infection (What is fungal infection?), hemiparesis. Evoltra dosage: 112 Iv, D 2, 4, 6, 8 + 10. During the same period patient was treated with CYTARABINE (100 Mg/m2 Cont Infus D1-10) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (10 Mg/m2, D1,3 And 5) (View Idarubicin Hcl Review and Idarubicin Hcl Label ). Patient was hospitalized.

6957463-7 | Aplasia, Blister, C-reactive Protein Increased, Capillary Leak Syndrome, Fatigue, Hepatorenal Syndrome, Multi-organ Failure, Palmar-plantar Erythrodysaesthesia Syndrome, Pyrexia
on Aug 23, 2010 Male patient from GERMANY , weighting 143.3 lb, was diagnosed with acute myeloid leukaemia, prophylaxis, vitamin d deficiency, pain (What is pain?) and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: aplasia, blister, c-reactive protein increased, capillary leak syndrome, fatigue, hepatorenal syndrome, multi-organ failure, palmar-plantar erythrodysaesthesia syndrome, pyrexia. Evoltra dosage: 30 Mg/m2, Qdx5. During the same period patient was treated with CYTARABINE (Unk Unk, Unk) (View Cytarabine Review and Cytarabine Label ), PANTOPRAZOLE SODIUM (40 Mg, Unk) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), VIGANTOLETTEN (1 G, Unk) (View Vigantoletten Review and Vigantoletten Label ), TRAMAL (10 Ng, Unk) (View Tramal Review and Tramal Label ), CLOTRIMAZOLE (20 Mg, Unk) (View Clotrimazole Review and Clotrimazole Label ), FLUCONAZOLE (200 Mg, Unk) (View Fluconazole Review and Fluconazole Label ), CORTISON (View Cortison Review and Cortison Label ), PIPERACILLIN AND TAZOBACTAM (View Piperacillin And Tazobactam Review and Piperacillin And Tazobactam Label ).

6944745-8 | Neutropenic Sepsis, Respiratory Failure
Patient was taking Evoltra (View Usage). Patient had the following side effects: neutropenic sepsis, respiratory failure on Aug 17, 2010 from NETHERLANDS Additional patient health information: Female patient , weighting 202.8 lb, was diagnosed with acute myeloid leukaemia and. Evoltra dosage: 21 Mg, Qdx5. During the same period patient was treated with CYTARABINE (420 Mg, Qd) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (25 Mg, Qdx3) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ZOVIRAX (450 Mg, Unk) (View Zovirax Review and Zovirax Label ), CANCIDAS (50 Mg, Once) (View Cancidas Review and Cancidas Label ), NEXIUM (40 Mg, Once) (View Nexium Review and Nexium Label ), POTASSIUM CHLORIDE (60 Mmol, Unk) (View Potassium Chloride Review and Potassium Chloride Label ), DAKTARIN (10 Mg, Unk) (View Daktarin Review and Daktarin Label ), SODIUM CHLORIDE (50 Ml, Unk) (View Sodium Chloride Review and Sodium Chloride Label ).

6919963-5 | Cytolytic Hepatitis, Hepatitis B Core Antigen Positive, Hepatitis B Surface Antigen Positive
Adverse event was reported on Jul 12, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 60 Mg/m2, Qd) was diagnosed with acute lymphocytic leukaemia, prophylaxis, antifungal treatment and. Location: FRANCE , 60 years of age, weighting 209.4 lb, After Evoltra was administered, patient had the following side effects: cytolytic hepatitis, hepatitis b core antigen positive, hepatitis b surface antigen positive. During the same period patient was treated with POLARAMINE (Unk) (View Polaramine Review and Polaramine Label ), ZOPHREN (1 Other, Unk) (View Zophren Review and Zophren Label ), ZYLORIC (300 Mg, Unk) (View Zyloric Review and Zyloric Label ), NOXAFIL (Unk) (View Noxafil Review and Noxafil Label ).

6910248-X | Anaemia, Bone Marrow Failure, Cholestasis, Decreased Appetite, Depressed Level Of Consciousness, Depression, Diarrhoea, Dyspnoea, Enterobacter Bacteraemia
on Jul 27, 2010 Female patient from BELGIUM , weighting 119.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, bone marrow failure, cholestasis, decreased appetite, depressed level of consciousness, depression (What is depression?), diarrhoea, dyspnoea, enterobacter bacteraemia. Evoltra dosage: 40 Mg/m2, Qdx5. During the same period patient was treated with FLUDARA (30 Mg/m2, Unk) (View Fludara Review and Fludara Label ), CYTARABINE (1 G/m2, Unk) (View Cytarabine Review and Cytarabine Label ), BUSULFAN (27 Mg, Unk) (View Busulfan Review and Busulfan Label ), ORGAMETRIL (View Orgametril Review and Orgametril Label ), XANAX (1.5 Mg, Unk) (View Xanax Review and Xanax Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), NOXAFIL (5 Ml, Tid) (View Noxafil Review and Noxafil Label ).

6905582-3 | Delirium, Dyspnoea, Haematuria, Infection, Pyrexia
on Jul 23, 2010 Female patient from NETHERLANDS , weighting 163.1 lb, was diagnosed with prophylaxis, pyrexia, delirium and was treated with Evoltra (View Usage). Patient had the following side effects: delirium, dyspnoea, haematuria, infection (What is infection?), pyrexia. Evoltra dosage: 10.5 Mg, Unk. During the same period patient was treated with CYTARABINE (370 Mg, Unk) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (22 Mg, Unk) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), IMIPENEM AND CILASTATIN (2000 Mg, Unk) (View Imipenem And Cilastatin Review and Imipenem And Cilastatin Label ), TOBRAMYCIN (360 Mg, Unk) (View Tobramycin Review and Tobramycin Label ), ESOMEPRAZOLE MAGNESIUM (20 Mg, Unk) (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), TRANEXAMIC ACID (4000 Mg, Unk) (View Tranexamic Acid Review and Tranexamic Acid Label ), VANCOMYCIN (2000 Mg, Unk) (View Vancomycin Review and Vancomycin Label ), HALOPERIDOL (9 Mg, Unk) (View Haloperidol Review and Haloperidol Label ).

6880558-3 | Optic Neuritis
Patient was taking Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: optic neuritis on Jul 16, 2010 from ITALY Additional patient health information: Male patient , weighting 132.3 lb, was diagnosed with acute myeloid leukaemia and. Evoltra dosage: Unk Unk, Unk. During the same period patient was treated with TEMSIROLIMUS (Unk Unk, Unk) (View Temsirolimus Review and Temsirolimus Label ). Patient was hospitalized.

6880538-8 | Ileus
Adverse event was reported on Jul 19, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 20 Mg/m2, Unk) was diagnosed with acute lymphocytic leukaemia, prophylaxis and. Location: NETHERLANDS , weighting 174.4 lb, Patient experienced the following unwanted or unexpected effects: ileus. During the same period patient was treated with ADRIAMYCIN PFS (83 Mg, Qd) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINCRISTINE (1 Mg, Qd) (View Vincristine Review and Vincristine Label ), PREDNISONE (25 Mg, Qd) (View Prednisone Review and Prednisone Label ), METHOTREXATE (15 Mg, Once) (View Methotrexate Review and Methotrexate Label ), DEXAMETHASONE (4 Mg, Once) (View Dexamethasone Review and Dexamethasone Label ), VALACYCLOVIR (1000 Mg, Qd) (View Valacyclovir Review and Valacyclovir Label ), TEMAZEPAM (10 Mg, Qd) (View Temazepam Review and Temazepam Label ). Patient was hospitalized.

6871031-7 | Cytolytic Hepatitis, Hepatitis B Core Antigen Positive, Hepatitis C Virus Test Positive
on Jul 12, 2010 Male patient from FRANCE , 60 years of age, weighting 209.4 lb, was diagnosed with acute lymphocytic leukaemia, prophylaxis, antifungal treatment and was treated with Evoltra (View Usage). Patient had the following side effects: cytolytic hepatitis, hepatitis b core antigen positive, hepatitis c virus test positive. Evoltra dosage: 60 Mg/m2, Qd. During the same period patient was treated with POLARAMINE (Unk) (View Polaramine Review and Polaramine Label ), ZOPHREN (1 Other, Unk) (View Zophren Review and Zophren Label ), ZYLORIC (300 Mg, Unk) (View Zyloric Review and Zyloric Label ), NOXAFIL (Unk) (View Noxafil Review and Noxafil Label ).

6866055-X | Delirium, Haematuria, Infection, Pyrexia
on Jul 14, 2010 Female patient from NETHERLANDS , weighting 163.1 lb, was diagnosed with prophylaxis, pyrexia, delirium and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: delirium, haematuria, infection (What is infection?), pyrexia. Evoltra dosage: 10.5 Mg, Unk. During the same period patient was treated with CYTARABINE (370 Mg, Unk) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (22 Mg, Unk) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), IMIPENEM AND CILASTATIN (2000 Mg, Unk) (View Imipenem And Cilastatin Review and Imipenem And Cilastatin Label ), TOBRAMYCIN (360 Mg, Unk) (View Tobramycin Review and Tobramycin Label ), ESOMEPRAZOLE MAGNESIUM (20 Mg, Unk) (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), TRANEXAMIC ACID (4000 Mg, Unk) (View Tranexamic Acid Review and Tranexamic Acid Label ), VANCOMYCIN (2000 Mg, Unk) (View Vancomycin Review and Vancomycin Label ), HALOPERIDOL (9 Mg, Unk) (View Haloperidol Review and Haloperidol Label ).

6866018-4 | Cytolytic Hepatitis, Hepatitis B Core Antigen Positive
Patient was taking Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: cytolytic hepatitis, hepatitis b core antigen positive on Jul 12, 2010 from FRANCE Additional patient health information: Male patient , 60 years of age, weighting 209.4 lb, was diagnosed with acute lymphocytic leukaemia, prophylaxis, antifungal treatment and. Evoltra dosage: 60 Mg/m2, Qd. During the same period patient was treated with POLARAMINE (Unk) (View Polaramine Review and Polaramine Label ), ZOPHREN (1 Other, Unk) (View Zophren Review and Zophren Label ), ZYLORIC (300 Mg, Unk) (View Zyloric Review and Zyloric Label ), NOXAFIL (Unk) (View Noxafil Review and Noxafil Label ).

6866008-1 | Pneumonia, Pyrexia, Renal Failure, Respiratory Failure, Respiratory Syncytial Virus Infection
Adverse event was reported on Jul 12, 2010 by a Female patient taking Evoltra (View Usage) (Dosage: 40 Mg/m2, Qdx5) was diagnosed with acute lymphocytic leukaemia, lung infection, neutropenia and. Location: PORTUGAL , weighting 55.12 lb, Patient had the following side effects: pneumonia (What is pneumonia?), pyrexia, renal failure, respiratory failure, respiratory syncytial virus infection (What is respiratory syncytial virus infection?). During the same period patient was treated with ETOPOSIDE (100 Mg/m2, Qdx5) (View Etoposide Review and Etoposide Label ), CYTOXAN (340 Mg/m2, Qdx5) (View Cytoxan Review and Cytoxan Label ), PIPERACILLIN W (2250 Mg, Unk) (View Piperacillin W Review and Piperacillin W Label ), AMICACINA (500 Unk, Unk) (View Amicacina Review and Amicacina Label ).

6861121-7 | Malignant Neoplasm Progression
on Jul 08, 2010 Male patient from FRANCE , weighting 231.5 lb, was diagnosed with myelodysplastic syndrome and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: malignant neoplasm progression. Evoltra dosage: 5 Mg/m2, Unk. During the same period patient was treated with VIDAZA (View Vidaza Review and Vidaza Label ).

6856196-5 | Cardiac Arrest, Dacryocystitis, Diarrhoea, Febrile Neutropenia, Hypokalaemia, Hyponatraemia, Organising Pneumonia
on Jul 09, 2010 Female patient from FRANCE , weighting 163.1 lb, was diagnosed with acute leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: cardiac arrest (What is cardiac arrest?), dacryocystitis, diarrhoea, febrile neutropenia, hypokalaemia, hyponatraemia, organising pneumonia. Evoltra dosage: 5 Mg/m2, Qdx5. During the same period patient was treated with CORTANCYL (5 Mg, Qd) (View Cortancyl Review and Cortancyl Label ), NEXIUM (40 Mg, Qd) (View Nexium Review and Nexium Label ), ISOPTIN (40 Mg, Tid) (View Isoptin Review and Isoptin Label ), MONICOR (20 Mg, Qd) (View Monicor Review and Monicor Label ), ALDACTAZINE (12.5 Mg, Qd) (View Aldactazine Review and Aldactazine Label ), TAVANIC (500 Mg, Tid) (View Tavanic Review and Tavanic Label ), NOXAFIL (200 Mg, Tid) (View Noxafil Review and Noxafil Label ), ZELITREX (500 Mg, Qd) (View Zelitrex Review and Zelitrex Label ). Patient was hospitalized.

6844434-4 | Blister, Ecchymosis, Febrile Neutropenia, Hyperkalaemia, Pancytopenia, Purpura, Rectal Haemorrhage, Thrombocytopenia
Patient was taking Evoltra (View Usage). Patient had the following side effects: blister, ecchymosis, febrile neutropenia, hyperkalaemia, pancytopenia, purpura, rectal haemorrhage, thrombocytopenia on Jul 01, 2010 from ROMANIA Additional patient health information: Male patient , weighting 180.8 lb, was diagnosed with acute myeloid leukaemia, febrile neutropenia, thrombocytopenia and. Evoltra dosage: 50 Mg, Qd. During the same period patient was treated with TAZOCIN (4.5 G, Qdx3) (View Tazocin Review and Tazocin Label ), METRONIDAZOLE (1 G, Bid) (View Metronidazole Review and Metronidazole Label ), VFEND (200 Unk, Bid) (View Vfend Review and Vfend Label ), RANITIDINE (1 Unk, Bid) (View Ranitidine Review and Ranitidine Label ), DEXAMETHASONE (40 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (35 Mg, Qd) (View Cytarabine Review and Cytarabine Label ).

6836056-6 | Febrile Neutropenia, Rectal Haemorrhage, Thrombocytopenia
Adverse event was reported on Jul 01, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 50 Mg, Qd) was diagnosed with acute myeloid leukaemia, febrile neutropenia, thrombocytopenia and. Location: ROMANIA , weighting 180.8 lb, After Evoltra was administered, patient had the following side effects: febrile neutropenia, rectal haemorrhage, thrombocytopenia. During the same period patient was treated with TAZOCIN (4.5 G, Qdx3) (View Tazocin Review and Tazocin Label ), METRONIDAZOLE (1 G, Bid) (View Metronidazole Review and Metronidazole Label ), VFEND (200 Unk, Bid) (View Vfend Review and Vfend Label ), RANITIDINE (1 Unk, Bid) (View Ranitidine Review and Ranitidine Label ), DEXAMETHASONE (40 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ), CYTARABINE (35 Mg, Qd) (View Cytarabine Review and Cytarabine Label ).

6826987-5 | Bone Marrow Failure, Human Herpesvirus 6 Infection
on Jun 29, 2010 Female patient from ITALY , 34 years of age, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, human herpesvirus 6 infection. Evoltra dosage: 22.5 Mg/m2, Qdx5. During the same period patient was treated with CYTARABINE (1 G/m2, Qdx5) (View Cytarabine Review and Cytarabine Label ), MYLOTARG (6 Mg/m2, Once) (View Mylotarg Review and Mylotarg Label ).

6826965-6 | Anaemia, Bone Marrow Failure, Cholestasis, Decreased Appetite, Depressed Level Of Consciousness, Depression, Diarrhoea, Dyspnoea
on Jun 25, 2010 Female patient from BELGIUM , weighting 119.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient had the following side effects: anaemia, bone marrow failure, cholestasis, decreased appetite, depressed level of consciousness, depression (What is depression?), diarrhoea, dyspnoea. Evoltra dosage: 40 Mg/m2, Qdx5. During the same period patient was treated with FLUDARA (30 Mg/m2, Unk) (View Fludara Review and Fludara Label ), CYTARABINE (1 G/m2, Unk) (View Cytarabine Review and Cytarabine Label ), BUSULFAN (27 Mg, Unk) (View Busulfan Review and Busulfan Label ), ORGAMETRIL (View Orgametril Review and Orgametril Label ), XANAX (Unk) (View Xanax Review and Xanax Label ), ZOLPIDEM (View Zolpidem Review and Zolpidem Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), NOXAFIL (5 Ml, Tid) (View Noxafil Review and Noxafil Label ).

6826493-8 | Anaemia, Antibiotic Resistant Staphylococcus Test Positive, Neutropenia, Sepsis, Thrombocytopenia
Patient was taking Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: anaemia, antibiotic resistant staphylococcus test positive, neutropenia, sepsis (What is sepsis?), thrombocytopenia on Jul 01, 2010 from ROMANIA Additional patient health information: Male patient , weighting 116.8 lb, was diagnosed with acute myeloid leukaemia and. Evoltra dosage: 50 Mg, Qdx5. During the same period patient was treated with ARA C (35 Mg, Qd) (View Ara-c Review and Ara-c Label ).

6815407-2 | Ileus
Adverse event was reported on Jun 22, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 20 Mg/m2, Unk) was diagnosed with acute lymphocytic leukaemia, prophylaxis and. Location: NETHERLANDS , weighting 174.4 lb, Patient experienced the following unwanted or unexpected effects: ileus. During the same period patient was treated with ADRIAMYCIN PFS (83 Mg, Qd) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINCRISTINE (1 Mg, Qd) (View Vincristine Review and Vincristine Label ), PREDNISONE (25 Mg, Qd) (View Prednisone Review and Prednisone Label ), METHOTREXATE (15 Mg, Once) (View Methotrexate Review and Methotrexate Label ), DEXAMETHASONE (4 Mg, Once) (View Dexamethasone Review and Dexamethasone Label ), VALACYCLOVIR (1000 Mg, Qd) (View Valacyclovir Review and Valacyclovir Label ), TEMAZEPAM (10 Mg, Qd) (View Temazepam Review and Temazepam Label ), CALCIUM CARBONATE (1000 Mg, Qd) (View Calcium Carbonate Review and Calcium Carbonate Label ). Patient was hospitalized.

6812324-9 | Infective Thrombosis, Pericardial Effusion, Pericarditis Infective
on Jun 21, 2010 Male patient from NETHERLANDS , weighting 418.9 lb, was diagnosed with acute myeloid leukaemia, acute leukaemia and was treated with Evoltra (View Usage). Patient had the following side effects: infective thrombosis, pericardial effusion, pericarditis infective. Evoltra dosage: Unk. During the same period patient was treated with CYTARABINE (Unk) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (Unk) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), AMSACRINE (265 Mg, Unk) (View Amsacrine Review and Amsacrine Label ), CETIRIZINE HCL (10 Mg, Unk) (View Cetirizine Hcl Review and Cetirizine Hcl Label ), ZOPICLON (7.5 Mg, Unk) (View Zopiclon Review and Zopiclon Label ), FRAXI (View Fraxi Review and Fraxi Label ).

6810136-3 | Accidental Overdose, Acute Hepatic Failure, Acute Myeloid Leukaemia Recurrent, Anuria, Apnoea, Ascites, Blister, Blood Pressure Systolic Increased, Bronchoalveolar Lavage Abnormal
on Jun 16, 2010 Female patient from GERMANY , weighting 130.1 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: accidental overdose, acute hepatic failure, acute myeloid leukaemia recurrent, anuria, apnoea, ascites, blister, blood pressure systolic increased, bronchoalveolar lavage abnormal. Evoltra dosage: 63 Mg, Qdx5. During the same period patient was treated with ARA C (1000 Mg/m2, Qdx5) (View Ara-c Review and Ara-c Label ), DEXTROSE (1000 Ml, Unk) (View Dextrose Review and Dextrose Label ), SODIUM CHLORIDE (1000 Ml, Qd) (View Sodium Chloride Review and Sodium Chloride Label ), POTASSIUM CHLORIDE (1000 Ml, Qd) (View Potassium Chloride Review and Potassium Chloride Label ), FORTECORTIN (8 Mg, Unk) (View Fortecortin Review and Fortecortin Label ), KEVATRIL (1 Mg, Unk) (View Kevatril Review and Kevatril Label ).

6784847-2 | Adenovirus Infection
Patient was taking Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: adenovirus infection on Mar 08, 2010 from IRELAND Additional patient health information: Female patient , weighting 20.28 lb, was diagnosed with acute leukaemia and. Evoltra dosage: 40 Mg/m2, Qdx5. During the same period patient was treated with METHOTREXATE (8 Mg, Unk) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (300 Mg/m2, Qdx5) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (100 Mg/m2, Qdx5) (View Etoposide Review and Etoposide Label ), PEG ASPARAGINASE (1000 U, Day 15) (View Peg-asparaginase Review and Peg-asparaginase Label ), DEXAMETHASONE ACETATE (10 Mg/m2, Qd (day 1-7)) (View Dexamethasone Acetate Review and Dexamethasone Acetate Label ).

6781908-9 | Infective Thrombosis, Pericardial Effusion, Pericarditis Infective
Adverse event was reported on Jun 08, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 22 Mg, Qdx5) was diagnosed with acute myeloid leukaemia, acute leukaemia and. Location: NETHERLANDS , weighting 418.9 lb, Patient had the following side effects: infective thrombosis, pericardial effusion, pericarditis infective. During the same period patient was treated with CYTARABINE (2200 Mg, Qdx5) (View Cytarabine Review and Cytarabine Label ), AMSACRINE (265 Mg, Unk) (View Amsacrine Review and Amsacrine Label ), CETIRIZINE HCL (10 Mg, Unk) (View Cetirizine Hcl Review and Cetirizine Hcl Label ), ZOPICLON (7.5 Mg, Unk) (View Zopiclon Review and Zopiclon Label ), FRAXI (View Fraxi Review and Fraxi Label ), DEXRUM (View Dexrum Review and Dexrum Label ).

6780183-9 | Acute Myeloid Leukaemia
on Jun 09, 2010 Female patient from AUSTRIA , weighting 110.2 lb, was diagnosed with acute myeloid leukaemia, prophylaxis, constipation (What is constipation?), prophylaxis of nausea and vomiting, dermatomyositis, pyrexia and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: acute myeloid leukaemia. Evoltra dosage: 30 Mg/m2, Qdx5. During the same period patient was treated with TROPISETRON (Unk Unk, Unk) (View Tropisetron Review and Tropisetron Label ), DAUNORUBICIN HCL (Unk) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (Unk) (View Cytarabine Review and Cytarabine Label ), DULCOLAX (Unk) (View Dulcolax Review and Dulcolax Label ), MOTILIUM (10 Mg, Qd) (View Motilium Review and Motilium Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), TAZONAM (5 G, Unk) (View Tazonam Review and Tazonam Label ).

6774742-7 | Ileus
on Jun 08, 2010 Male patient from NETHERLANDS , weighting 174.4 lb, was diagnosed with acute lymphocytic leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: ileus. Evoltra dosage: 20 Mg/m2, Unk. During the same period patient was treated with ADRIAMYCIN PFS (Unk) (View Adriamycin Pfs Review and Adriamycin Pfs Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6774723-3 | Haematotoxicity
Patient was taking Evoltra (View Usage). Patient had the following side effects: haematotoxicity on Jun 07, 2010 from GREECE Additional patient health information: Male patient , 18 years of age, was diagnosed with acute lymphocytic leukaemia and. Evoltra dosage: 52 Mg/m2, Qdx5.

6774710-5 | Haematotoxicity, Transaminases Increased
Adverse event was reported on Jun 07, 2010 by a Female patient taking Evoltra (View Usage) (Dosage: 52 Mg/m2, Qdx5) was diagnosed with acute lymphocytic leukaemia and. Location: GREECE , child 12 years of age, After Evoltra was administered, patient had the following side effects: haematotoxicity, transaminases increased.

6763815-0 | Blood Creatinine Increased, Hyperkalaemia, Neutropenic Sepsis, Palmar-plantar Erythrodysaesthesia Syndrome, Pancytopenia, Respiratory Failure
on May 27, 2010 Female patient from NETHERLANDS , weighting 202.8 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, hyperkalaemia, neutropenic sepsis, palmar-plantar erythrodysaesthesia syndrome, pancytopenia, respiratory failure. Evoltra dosage: 21 Mg, Qdx5. During the same period patient was treated with CYTARABINE (420 Mg, Qd) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (25 Mg, Qdx3) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ZOVIRAX (450 Mg, Unk) (View Zovirax Review and Zovirax Label ), CANCIDAS (50 Mg, Once) (View Cancidas Review and Cancidas Label ), NEXIUM (40 Mg, Once) (View Nexium Review and Nexium Label ), POTASSIUM CHLORIDE (60 Mmol, Unk) (View Potassium Chloride Review and Potassium Chloride Label ), DAKTARIN (10 Mg, Unk) (View Daktarin Review and Daktarin Label ), SODIUM CHLORIDE (50 Ml, Unk) (View Sodium Chloride Review and Sodium Chloride Label ).

6762460-0 | Malignant Neoplasm Progression
on May 27, 2010 Male patient from FRANCE , weighting 231.5 lb, was treated with Evoltra (View Usage). Patient had the following side effects: malignant neoplasm progression. Evoltra dosage: 5 Mg/m2, Unk.

6762419-3 | Dermatitis Exfoliative
Patient was taking Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: dermatitis exfoliative on May 28, 2010 from NETHERLANDS Additional patient health information: Male patient , weighting 163.1 lb, . Evoltra dosage: 10 Mg/m2, Unk. During the same period patient was treated with AMSACRINE (120 Mg/m2, Unk) (View Amsacrine Review and Amsacrine Label ), CYTARABINE (1000 Mg/m2, Unk) (View Cytarabine Review and Cytarabine Label ).

6761110-7 | Pericardial Effusion, Staphylococcal Sepsis, Thrombosis In Device
Adverse event was reported on May 26, 2010 by a Male patient taking Evoltra (View Usage) (Dosage: 22 Mg, Qdx5) was diagnosed with acute leukaemia and. Location: NETHERLANDS , weighting 418.9 lb, Patient experienced the following unwanted or unexpected effects: pericardial effusion, staphylococcal sepsis, thrombosis in device. During the same period patient was treated with CYTARABINE (2200 Mg, Qdx5) (View Cytarabine Review and Cytarabine Label ), AMSACRINE (265 Mg, Unk) (View Amsacrine Review and Amsacrine Label ), CETIRIZINE HCL (10 Mg, Unk) (View Cetirizine Hcl Review and Cetirizine Hcl Label ), ZOPICLON (7.5 Mg, Unk) (View Zopiclon Review and Zopiclon Label ), FRAXI (View Fraxi Review and Fraxi Label ), DEXRUM (View Dexrum Review and Dexrum Label ).

6751131-2 | Acute Hepatic Failure, Capillary Leak Syndrome, Cardiac Failure, Renal Failure Acute, Sepsis, Somnolence
on May 20, 2010 Female patient from GERMANY , weighting 130.1 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient had the following side effects: acute hepatic failure, capillary leak syndrome, cardiac failure, renal failure acute, sepsis (What is sepsis?), somnolence. Evoltra dosage: 63 Mg, Qdx5. During the same period patient was treated with GLUCOSE (1000 Ml, Unk) (View Glucose Review and Glucose Label ), SODIUM CHLORIDE (1000 Ml, Unk) (View Sodium Chloride Review and Sodium Chloride Label ), POTASSIUM CHLORIDE (Unk) (View Potassium Chloride Review and Potassium Chloride Label ), FORTECORTIN (Unk) (View Fortecortin Review and Fortecortin Label ), KEVATRIL (1 Mg, Unk) (View Kevatril Review and Kevatril Label ).

6749065-2 | Cholestasis, Encephalopathy, Enterobacter Bacteraemia, Enterococcal Bacteraemia, Hyperbilirubinaemia, Palmar-plantar Erythrodysaesthesia Syndrome, Paraplegia, Peripheral Motor Neuropathy, Peripheral Sensory Neuropathy
on May 18, 2010 Female patient from BELGIUM , weighting 119.0 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: cholestasis, encephalopathy, enterobacter bacteraemia, enterococcal bacteraemia, hyperbilirubinaemia, palmar-plantar erythrodysaesthesia syndrome, paraplegia, peripheral motor neuropathy, peripheral sensory neuropathy. Evoltra dosage: 40 Mg/m2, Qdx5. During the same period patient was treated with FLUDARA (30 Mg/m2, Unk) (View Fludara Review and Fludara Label ), CYTARABINE (1 G/m2, Unk) (View Cytarabine Review and Cytarabine Label ), BUSULFEX (2 Mg/kg, Unk) (View Busulfex Review and Busulfex Label ).

6745870-7 | Anaemia, Antibiotic Resistant Staphylococcus Test Positive, Neutropenia, Sepsis, Thrombocytopenia
Patient was taking Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: anaemia, antibiotic resistant staphylococcus test positive, neutropenia, sepsis (What is sepsis?), thrombocytopenia on May 14, 2010 from ROMANIA Additional patient health information: Male patient , weighting 116.8 lb, was diagnosed with acute myeloid leukaemia and. Evoltra dosage: 50 Mg, Qdx5.

6744522-7 | Disease Progression
Adverse event was reported on May 17, 2010 by a Female patient taking Evoltra (View Usage) (Dosage: 30 Mg/m2, Qdx5) was diagnosed with acute myeloid leukaemia, prophylaxis, constipation (What is constipation?), prophylaxis of nausea and vomiting, dermatomyositis, pyrexia and. Location: AUSTRIA , weighting 110.2 lb, Patient had the following side effects: disease progression. During the same period patient was treated with TROPISETRON (Unk Unk, Unk) (View Tropisetron Review and Tropisetron Label ), DAUNORUBICIN HCL (Unk) (View Daunorubicin Hcl Review and Daunorubicin Hcl Label ), CYTARABINE (Unk) (View Cytarabine Review and Cytarabine Label ), DULCOLAX (Unk) (View Dulcolax Review and Dulcolax Label ), MOTILIUM (10 Mg, Qd) (View Motilium Review and Motilium Label ), DIFLUCAN (View Diflucan Review and Diflucan Label ), TAZONAM (5 G, Unk) (View Tazonam Review and Tazonam Label ).

6741433-8 | Rectal Haemorrhage
on May 14, 2010 Male patient from ROMANIA , weighting 180.8 lb, was diagnosed with acute myeloid leukaemia, prophylaxis and was treated with Evoltra (View Usage). After Evoltra was administered, patient had the following side effects: rectal haemorrhage. Evoltra dosage: 50 Mg, Qd. During the same period patient was treated with TAZOCIN (4.5 G, Qdx3) (View Tazocin Review and Tazocin Label ), METRONIDAZOLE (1 G, Bid) (View Metronidazole Review and Metronidazole Label ), VFEND (200 Unk, Bid) (View Vfend Review and Vfend Label ), RANITIDINE (1 Unk, Bid) (View Ranitidine Review and Ranitidine Label ), DEXAMETHASONE (40 Mg, Unk) (View Dexamethasone Review and Dexamethasone Label ).

6739589-6 | Blood Creatinine Increased, Hyperkalaemia, Palmar-plantar Erythrodysaesthesia Syndrome, Pancytopenia, Respiratory Failure
on May 12, 2010 Female patient from NETHERLANDS , weighting 202.8 lb, was diagnosed with acute myeloid leukaemia and was treated with Evoltra (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, hyperkalaemia, palmar-plantar erythrodysaesthesia syndrome, pancytopenia, respiratory failure. Evoltra dosage: 21 Mg, Qdx5. During the same period patient was treated with CYTARABINE (420 Mg, Qd) (View Cytarabine Review and Cytarabine Label ), IDARUBICIN HCL (25 Mg, Qdx3) (View Idarubicin Hcl Review and Idarubicin Hcl Label ), ZOVIRAX (450 Mg, Unk) (View Zovirax Review and Zovirax Label ), CANCIDAS (50 Mg, Once) (View Cancidas Review and Cancidas Label ), NEXIUM (40 Mg, Once) (View Nexium Review and Nexium Label ), POTASSIUM CHLORIDE (60 Mmol, Unk) (View Potassium Chloride Review and Potassium Chloride Label ), DAKTARIN (10 Mg, Unk) (View Daktarin Review and Daktarin Label ), SODIUM CHLORIDE (50 Ml, Unk) (View Sodium Chloride Review and Sodium Chloride Label ).

6736235-2 | Aplasia, Blister, C-reactive Protein Increased, Capillary Leak Syndrome, Fatigue, Hepatorenal Syndrome, Multi-organ Failure, Palmar-plantar Erythrodysaesthesia Syndrome, Pyrexia
Patient was taking Evoltra (View Usage). Patient had the following side effects: aplasia, blister, c-reactive protein increased, capillary leak syndrome, fatigue, hepatorenal syndrome, multi-organ failure, palmar-plantar erythrodysaesthesia syndrome, pyrexia on May 10, 2010 from GERMANY Additional patient health information: Male patient , weighting 143.3 lb, was diagnosed with acute myeloid leukaemia, prophylaxis, vitamin d deficiency, pain (What is pain?) and. Evoltra dosage: 30 Mg/m2, Qdx5. During the same period patient was treated with CYTARABINE (Unk Unk, Unk) (View Cytarabine Review and Cytarabine Label ), PANTOPRAZOLE SODIUM (40 Mg, Unk) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), VIGANTOLETTEN (1 G, Unk) (View Vigantoletten Review and Vigantoletten Label ), TRAMAL (10 Ng, Unk) (View Tramal Review and Tramal Label ), CLOTRIMAZOLE (20 Mg, Unk) (View Clotrimazole Review and Clotrimazole Label ), FLUCONAZOLE (200 Mg, Unk) (View Fluconazole Review and Fluconazole Label ), CORTISON (View Cortison Review and Cortison Label ), PIPERACILLIN AND TAZOBACTAM (View Piperacillin And Tazobactam Review and Piperacillin And Tazobactam Label ).